An candidate vaccine developed by China based on a virus inactivated from SARS-CoV-2 (the name of new coronavirus) proved to be safe and able to stimulate the production of antibodies, according to the result of a preliminary test made public last Thursday, 15, in the specialized publication The Lancet Infectious Diseases journal.
The tests were carried out between April 29 and July 30 this year, with researchers from different Chinese institutions, including the Beijing Institute of Biological Products. They were submitted to 600 healthy patients aged between 18 and 80 years.
The study found stimulus to the production of antibodies in all patients in an interval of 42 days, without any adverse reaction.
The research team said that the objective of the test at this stage of development was mainly to assess the immune response and the safety of the vaccine and that it is still not possible to confirm that the candidate is sufficient to protect people from infection caused by the new coronavirus. Therefore, new tests in the third and last phase and new analyzes will be necessary.
The vaccine whose results were positive is not the one developed by the Chinese biotechnology company Sinovac, with which the São Paulo government has a wide distribution agreement if it is even approved for commercialization.